| Id: | acc1433 |
| Group: | 2sens |
| Protein: | AKT |
| Gene Symbol: | Akt1 |
| Protein Id: | P31750 |
| Protein Name: | AKT1_MOUSE |
| PTM: | phosphorylation |
| Site: | Ser473 |
| Site Sequence: | ERRPHFPQFSYSASGTA---- |
| Disease Category: | Cancer |
| Disease: | Leukemia |
| Disease Subtype: | "CML, imatinib-res, E255K" |
| Disease Cellline: | DA1-3b/M1 |
| Disease Info: | |
| Drug: | imatinib |
| Drug Info: | "Imatinib is a tyrosine kinase inhibitor that targets Bcr-Abl and KIT proteins, used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST)." |
| Effect: | inhibit |
| Effect Info: | "GILZ inhibits the phosphorylation of AKT, making drug-resistant cells sensitive to imatinib." |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 21804606 |
| Sentence Index: | 21804606_5-6 |
| Sentence: | "In mouse and human models, GILZ binds to mTORC2, but not to mTORC1, inhibiting phosphorylation of AKT (at Ser473) and activating FoxO3a-mediated transcription of the pro-apoptotic protein Bim; these results demonstrate that GILZ is a key inhibitor of the mTORC2 pathway. Furthermore, CD34(+) stem cells isolated from relapsing CML patients underwent apoptosis and showed inhibition of mTORC2 after incubation with glucocorticoids and imatinib." |
Sequence & Structure:
MNDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQRESPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWATAIQTVADGLKRQEEETMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPTQRLGGGSEDAKEIMQHRFFANIVWQDVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 473 | D | Alzheimer's disease | Phosphorylation | 35834993 ; 36843923 |
| S | 473 | D | Colonic inflammation | Phosphorylation | 36735734 |
| S | 473 | D | Diabetes mellitus | Phosphorylation | 17130464 ; 16777975 ; 15033922 ; 15033922 ; 16777975 ; 17130464 ; 35739993 |
| S | 473 | D | Turner syndrome | Phosphorylation | 33910978 |
| S | 473 | U | Cardiomyopathy | Phosphorylation | 35358489 |
| S | 473 | U | Diabetes mellitus | Phosphorylation | 35358489 |
| S | 473 | U | Endometrial cancer/carcinoma | Phosphorylation | 16585156 |
| S | 473 | U | Melanoma | Phosphorylation | 26565903 |
| S | 473 | U | Non-small cell lung cancer | Phosphorylation | 35961388 |
| S | 473 | U | Hepatocellular carcinoma | Phosphorylation | 33500384 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
